Latest news with #EuropeanCongressofRadiology
Yahoo
26-02-2025
- Business
- Yahoo
GE HealthCare unveils Freelium, a next-generation sealed magnet platform at ECR 2025 to support equitable and sustainable access to MR
Freelium, a helium-freei sealed magnet platform in development, aims to dramatically reduce liquid helium usage without sacrificing power efficiency, operational security and clinical performance Leveraging GE HealthCare's proven lightweight, intelligent magnet technology, Freelium will be optimized to seamlessly integrate with future technological advancements and upgrade options, offering flexibility and reliability for imaging departments CHICAGO, February 26, 2025--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today unveiled Freelium™,ii a next-generation sealed magnet platform, that aims to enable high-quality Magnetic Resonance (MR) imaging with less than 1% of helium used in conventional magnet technology to help support diagnostic accuracy and sustainability goals. Debuting at the European Congress of Radiology (ECR), Freelium marks the evolution of GE HealthCare's established lightweight intelligent platform magnet technology, which was first introduced in 2020, now with over 2,000 installations worldwide at 1.5T and 3.0T magnetic fields. Freelium is designed to significantly reduce liquid helium usage without compromising power efficiency and operational security. To maintain power efficiency, Freelium aims to operate with no additional cooling and power requirements. Additionally, the platform's intelligent sensor technology intends to remotely monitor the MR system and enable automated magnet protection and recovery capability without the need for field engineer intervention. This is particularly important in the event of power outages or disruptions caused by natural events. To support diagnostic accuracy and confidence, Freelium aims to uphold GE HealthCare's advanced quality and performance standards. The platform also will be optimized to be compatible with GE HealthCare's leading AI-enabled solutions. Freelium magnets will be able to be transported and installed in hospitals and in markets where access to helium is limited and without significant helium loss during transport, enhancing patient access to care. "Today's unveiling of Freelium reinforces our commitment to provide equitable and sustainable access to MR to any patient and user, while maintaining imaging performance and ensuring seamless operational security for our customers," said Kelly Londy, President & CEO, Global MR, GE HealthCare. "We're excited about Freelium's compatibility with AI-enabled solutions and ability to unlock the full potential of deep learning applications for enhanced diagnostic insights in the future." With the Freelium platform, GE HealthCare is committed to achieving its sustainability goals by advancing environmentally conscious design from manufacturing and throughout the life cycle of the platform. Through the company's intelligent magnet technology and Continuum™ upgrades, GE HealthCare has saved approximately 3 million liters of helium. To learn more about GE HealthCare's Freelium and other MRI technology, please visit or the company's booth at ECR 2025. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. [i] Helium-free: Helium is permanently enclosed in the magnet.[ii]Technology in development that represents ongoing research and development efforts. Not for sale. Not CE marked. Not cleared or approved by the US FDA or any other global regulator for commercial availability. View source version on Contacts GE HealthCare Media Contact: Katie ScrivanoM +1 Sign in to access your portfolio
Yahoo
26-02-2025
- Business
- Yahoo
Late-breaking data from QUANTI CNS (Central Nervous System) presented at ECR 2025:
Positive results from Phase III study for Bayer's investigational contrast agent gadoquatrane First Phase III results from the clinical development program QUANTI on investigational MRI contrast agent gadoquatrane presented as late-breaking data during a scientific session at the 2025 European Congress of Radiology (ECR) QUANTI CNS met the primary endpoints of non-inferiority of gadoquatrane across visualization parameters using a 60 percent lower gadolinium dose compared to macrocyclic gadolinium-based contrast agents dosed at 0.1 mmol Gd/kg body weight and demonstrated superiority compared to unenhanced MRI Secondary endpoints sensitivity and specificity for the detection of lesions were met by showing non-inferiority to the comparator MRI contrast agents Bayer plans to submit the data to health authorities worldwide to secure marketing authorization for gadoquatrane Not intended for UK Media WHIPPANY, N.J., February 26, 2025--(BUSINESS WIRE)--Bayer, a global leader in radiology, announced positive results from the Phase III study QUANTI CNS, which evaluated the investigational gadolinium-based contrast agent (GBCA) gadoquatrane in adults with known or suspected pathologies of the central nervous system undergoing contrast-enhanced magnetic resonance imaging (MRI). QUANTI CNS is part of Bayer's pivotal QUANTI clinical development program consisting of two multinational Phase III studies in adults as well as a pediatric study. In all studies, gadoquatrane was investigated at a gadolinium dose of 0.04 mmol Gd/kg body weight which represents a gadolinium dose reduction of 60 percent compared to the macrocyclic GBCAs dosed at 0.1 mmol Gd/kg body weight. The detailed results of QUANTI CNS were revealed as late-breaking clinical trial data at this year's annual European Congress of Radiology (ECR), taking place at Vienna, Austria, from February 26 to March 2, 2025. "Contrast-enhanced magnetic resonance imaging is one of the most powerful diagnostic tools in contemporary clinical medicine, offering unparalleled insight into the human body," said principal investigator Dr. Benjamin P. Liu, Associate Professor of Radiology and Radiation Oncology, Northwestern University Feinberg School of Medicine, Chicago, USA. "A reduced gadolinium dose could be particularly valuable for patients suffering from central nervous system pathologies, as many of them undergo multiple MRI examinations along their diagnostic and treatment pathway and it is always advisable to administer the lowest efficacious dose of any drug. The results of the QUANTI CNS study highlight the potential of a reduced gadolinium dose demonstrating non-inferiority to the other comparator gadolinium-based contrast agents in the clinical trial. This has the potential to benefit both current and future generations of patients and healthcare professionals." Detailed study results of QUANTI CNS evaluating the efficacy and safety of gadoquatrane in adults with known or suspected pathologies of the central nervous system undergoing a contrast-enhanced MRI show that gadoquatrane met all primary and secondary study objectives. Non-inferior diagnostic efficacy to comparator macrocyclic GBCAs (gadobutrol, gadoterate meglumine/gadoteric acid, gadoteridol) dosed at 0.1 mmol Gd/kg body weight was demonstrated by a blinded central independent read using the three established visualization parameters – contrast enhancement, delineation, and morphology. Gadoquatrane also achieved non-inferior diagnostic performance to the trial comparators based on the sensitivity and specificity for the detection or exclusion of lesions. When compared to MRIs without contrast injection, gadoquatrane demonstrated superiority based on the visualization parameters. In total, QUANTI CNS included 305 patients from 16 countries in Europe, Asia, and America. The safety events observed with gadoquatrane were similar to those observed for the comparator macrocyclic GBCAs with a low incidence of intervention related treatment emergent adverse events and generally consistent with previous data on gadoquatrane and other macrocyclic GBCAs. "The burden of neurological disorders impacts millions of patients around the world and is set to rise during the next decades," said Dr. Konstanze Diefenbach, Head of Radiology Research & Development, Bayer. "We are very pleased about the positive results shown in QUANTI CNS. We look forward to working with regulatory authorities worldwide, aiming to make gadoquatrane available for patients and their treating physicians as a new low dose option in contrast-enhanced MRI." In January 2025, Bayer announced positive topline data for the QUANTI study program, showing that gadoquatrane met the primary and main secondary endpoints of all studies. The results from QUANTI CNS were presented for the first time at ECR. The results of QUANTI OBR, which investigated the safety and efficacy of gadoquatrane in contrast-enhanced MRI of all other body regions, and QUANTI Pediatric assessing the pharmacokinetics and safety of gadoquatrane in children from birth to < 18 years of age are planned to be presented at upcoming scientific congresses. Bayer plans to submit a comprehensive data package which will include the study results to health authorities worldwide to secure marketing authorization for gadoquatrane. About gadoquatraneGadoquatrane is Bayer's investigational extracellular macrocyclic contrast agent in clinical development for contrast enhancement in MRI. This gadolinium-based contrast agent features a distinct tetrameric structure with high stability and high relaxivity. About MRIWith an estimated 65 million procedures performed annually worldwide, contrast-enhanced MRI plays a key role in the healthcare continuum. MRI is a non-invasive, radiation-free imaging method that provides detailed images of the body, helping to identify and distinguish potential abnormalities in organs and tissues. This supports physicians in answering critical medical questions related to the detection, characterization, and monitoring of diseases. About Radiology at BayerAs a true life-science company with a heritage of over 100 years in radiology, Bayer is committed to providing excellence – from innovative products to high-quality services – to support efficient and optimized patient care. Bayer offers a leading portfolio of contrast media for computed tomography (CT), X-ray, and magnetic resonance imaging (MRI), along with devices for their precise administration, informatics solutions, and a medical imaging platform delivering access to applications, including those enabled by AI. Bayer's radiology products generated about € 2 billion euros in sales in 2023. Bayer is highly committed to research and development, which includes leveraging AI and driving innovation in medical imaging. About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to vvi (2025-000xe) Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. View source version on Contacts Bayer Contact for global media inquiries: Victoria Vigener, phone +49 151 23438911 Email: Bayer Contact for US media inquiries: Jennifer May, phone +1 (412) 656-8192 Email: Find more information at Follow us on Facebook: Follow us on Twitter: @BayerPharma Sign in to access your portfolio
Yahoo
26-02-2025
- Business
- Yahoo
Late-breaking data from QUANTI CNS (Central Nervous System) presented at ECR 2025:
Positive results from Phase III study for Bayer's investigational contrast agent gadoquatrane First Phase III results from the clinical development program QUANTI on investigational MRI contrast agent gadoquatrane presented as late-breaking data during a scientific session at the 2025 European Congress of Radiology (ECR) QUANTI CNS met the primary endpoints of non-inferiority of gadoquatrane across visualization parameters using a 60 percent lower gadolinium dose compared to macrocyclic gadolinium-based contrast agents dosed at 0.1 mmol Gd/kg body weight and demonstrated superiority compared to unenhanced MRI Secondary endpoints sensitivity and specificity for the detection of lesions were met by showing non-inferiority to the comparator MRI contrast agents Bayer plans to submit the data to health authorities worldwide to secure marketing authorization for gadoquatrane Not intended for UK Media WHIPPANY, N.J., February 26, 2025--(BUSINESS WIRE)--Bayer, a global leader in radiology, announced positive results from the Phase III study QUANTI CNS, which evaluated the investigational gadolinium-based contrast agent (GBCA) gadoquatrane in adults with known or suspected pathologies of the central nervous system undergoing contrast-enhanced magnetic resonance imaging (MRI). QUANTI CNS is part of Bayer's pivotal QUANTI clinical development program consisting of two multinational Phase III studies in adults as well as a pediatric study. In all studies, gadoquatrane was investigated at a gadolinium dose of 0.04 mmol Gd/kg body weight which represents a gadolinium dose reduction of 60 percent compared to the macrocyclic GBCAs dosed at 0.1 mmol Gd/kg body weight. The detailed results of QUANTI CNS were revealed as late-breaking clinical trial data at this year's annual European Congress of Radiology (ECR), taking place at Vienna, Austria, from February 26 to March 2, 2025. "Contrast-enhanced magnetic resonance imaging is one of the most powerful diagnostic tools in contemporary clinical medicine, offering unparalleled insight into the human body," said principal investigator Dr. Benjamin P. Liu, Associate Professor of Radiology and Radiation Oncology, Northwestern University Feinberg School of Medicine, Chicago, USA. "A reduced gadolinium dose could be particularly valuable for patients suffering from central nervous system pathologies, as many of them undergo multiple MRI examinations along their diagnostic and treatment pathway and it is always advisable to administer the lowest efficacious dose of any drug. The results of the QUANTI CNS study highlight the potential of a reduced gadolinium dose demonstrating non-inferiority to the other comparator gadolinium-based contrast agents in the clinical trial. This has the potential to benefit both current and future generations of patients and healthcare professionals." Detailed study results of QUANTI CNS evaluating the efficacy and safety of gadoquatrane in adults with known or suspected pathologies of the central nervous system undergoing a contrast-enhanced MRI show that gadoquatrane met all primary and secondary study objectives. Non-inferior diagnostic efficacy to comparator macrocyclic GBCAs (gadobutrol, gadoterate meglumine/gadoteric acid, gadoteridol) dosed at 0.1 mmol Gd/kg body weight was demonstrated by a blinded central independent read using the three established visualization parameters – contrast enhancement, delineation, and morphology. Gadoquatrane also achieved non-inferior diagnostic performance to the trial comparators based on the sensitivity and specificity for the detection or exclusion of lesions. When compared to MRIs without contrast injection, gadoquatrane demonstrated superiority based on the visualization parameters. In total, QUANTI CNS included 305 patients from 16 countries in Europe, Asia, and America. The safety events observed with gadoquatrane were similar to those observed for the comparator macrocyclic GBCAs with a low incidence of intervention related treatment emergent adverse events and generally consistent with previous data on gadoquatrane and other macrocyclic GBCAs. "The burden of neurological disorders impacts millions of patients around the world and is set to rise during the next decades," said Dr. Konstanze Diefenbach, Head of Radiology Research & Development, Bayer. "We are very pleased about the positive results shown in QUANTI CNS. We look forward to working with regulatory authorities worldwide, aiming to make gadoquatrane available for patients and their treating physicians as a new low dose option in contrast-enhanced MRI." In January 2025, Bayer announced positive topline data for the QUANTI study program, showing that gadoquatrane met the primary and main secondary endpoints of all studies. The results from QUANTI CNS were presented for the first time at ECR. The results of QUANTI OBR, which investigated the safety and efficacy of gadoquatrane in contrast-enhanced MRI of all other body regions, and QUANTI Pediatric assessing the pharmacokinetics and safety of gadoquatrane in children from birth to < 18 years of age are planned to be presented at upcoming scientific congresses. Bayer plans to submit a comprehensive data package which will include the study results to health authorities worldwide to secure marketing authorization for gadoquatrane. About gadoquatraneGadoquatrane is Bayer's investigational extracellular macrocyclic contrast agent in clinical development for contrast enhancement in MRI. This gadolinium-based contrast agent features a distinct tetrameric structure with high stability and high relaxivity. About MRIWith an estimated 65 million procedures performed annually worldwide, contrast-enhanced MRI plays a key role in the healthcare continuum. MRI is a non-invasive, radiation-free imaging method that provides detailed images of the body, helping to identify and distinguish potential abnormalities in organs and tissues. This supports physicians in answering critical medical questions related to the detection, characterization, and monitoring of diseases. About Radiology at BayerAs a true life-science company with a heritage of over 100 years in radiology, Bayer is committed to providing excellence – from innovative products to high-quality services – to support efficient and optimized patient care. Bayer offers a leading portfolio of contrast media for computed tomography (CT), X-ray, and magnetic resonance imaging (MRI), along with devices for their precise administration, informatics solutions, and a medical imaging platform delivering access to applications, including those enabled by AI. Bayer's radiology products generated about € 2 billion euros in sales in 2023. Bayer is highly committed to research and development, which includes leveraging AI and driving innovation in medical imaging. About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to vvi (2025-000xe) Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. View source version on Contacts Bayer Contact for global media inquiries: Victoria Vigener, phone +49 151 23438911 Email: Bayer Contact for US media inquiries: Jennifer May, phone +1 (412) 656-8192 Email: Find more information at Follow us on Facebook: Follow us on Twitter: @BayerPharma Sign in to access your portfolio
Associated Press
24-02-2025
- Business
- Associated Press
Median Technologies to Showcase Its Artificial Intelligence Software as a Medical Device for Lung Cancer Screening, eyonis™ LCS, at the European Congress of Radiology
Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, 'Median' or 'The Company'), a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of AI-powered imaging analyses and central imaging services for oncology drug developers, today announced that it will attend the European Congress of Radiology (ECR) 2025 in Vienna, from Feb. 26 to March 2. The Median eyonis™ team will welcome interested parties at Booth #AI-18, AI Exhibition, Expo X1, from February 26 to March 1 (technical exhibits dates). The Company will share the latest developments for eyonis™ Lung Cancer Screening (LCS) Software as a Medical Device (SaMD). The Company recently reported that eyonis™ LCS, its AI-powered SaMD for Lung Cancer Screening met the primary endpoint with statistical significance in RELIVE, the second of two successful pivotal studies required for marketing authorizations in US and Europe ( identifier ID NCT06751576). RELIVE secondary endpoints results will be communicated as soon as all the statistical analyses are finalized. The protocol and primary endpoints for the two pivotal studies, RELIVE and REALITY, were defined in accordance with discussions held with the FDA. By achieving the primary endpoints in both pivotal studies, eyonis™ LCS has successfully completed the regulatory requirements for clinical validation. Consequently, the regulatory dossiers for obtaining the U.S. 510(k) and European CE marking of eyonis™ LCS will be submitted to the agencies in the second quarter of this year. 'The recently reported pivotal study results suggest eyonis™ LCS may enable broad implementation of LDCT lung cancer screening procedures by improving lung cancer diagnosis accuracy and addressing the bottlenecks of complexity and time required for analyzing LDCT images,' said Thomas Bonnefont, COO and CCO of the eyonis™ Business Unit at Median Technologies. ' Based on our strong pivotal results, we are now looking towards our filings for marketing authorizations, in both the US and Europe, in Q2 2025, as soon as we finish the analysis. We will report RELIVE secondary endpoints results in the coming weeks. In the interim, we are very pleased to share the eyonis™ LCS pivotal study results already available, and discuss the game changing potential of our Software as a Medical Device with the radiology community at the European Congress of Radiology', Thomas Bonnefont added. Median's eyonis™ team will present at ECR: Industry Presentation: 'eyonis™ LCS: Pioneering AI/ML Software as a Medical Device Redefining the Future of Lung Cancer Screening' Presenter: Valérie Bourdès, MD, VP Clinical and Medical Affairs, eyonis™ - Median Technologies Session AI-IND 3 - AI Lightning Talks 3 Wednesday, February 26 - 13:30 – 14:30 CET AI Theatre, ACV Building Level -2 Concurrently, Median's iCRO team will present: Author: Hubert Beaumont, Lead Scientist, Median Technologies Research Presentation Session: Oncologic Imaging Session: RPS 116 - Staging, metastases and response assessment Wednesday, February 26 – 8:00 – 9:30 CET ACV Building, Research Stage 3 About eyonis™ LCS: eyonis™ Lung Cancer Screening (LCS) is an AI/ML-enabled Software as a Medical Device that uses machine learning to analyze imaging data generated with low dose computed tomography (LDCT). eyonis™ LCS aids to diagnose lung cancer at the earliest stages, when it can still be cured in many patients. eyonis™ LCS is the subject of two pivotal studies required for marketing approvals in the U.S. and Europe: REALITY (successfully completed - ID: NCT06576232) and RELIVE (primary endpoint successfully achieved, secondary endpoints analysis on-going - ID: NCT06751576). Filing applications including these pivotal data are scheduled to be submitted for FDA 510(k) clearance and CE marking in Q2 2025. About Median Technologies: Pioneering innovative imaging solutions and Software as a Medical Device, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit Forward-Looking Statements This press release contains forward-looking statements. These statements are not historical facts. They include projections and estimates as well as the assumptions on which these are based, statements concerning projects, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, or future performance. These forward-looking statements can often be identified by the words 'expects,' 'anticipates,' 'believes,' 'intends,' 'estimates' or 'plans' and any other similar expressions. Although Median's management believes that these forward-looking statements are reasonable, investors are cautioned that forward-looking statements are subject to numerous risks and uncertainties, many of which are difficult to predict and generally beyond the control of Median Technologies, that could cause actual results and events to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. All forward-looking statements in this press release are based on information available to Median Technologies as of the date of the press release. Median Technologies does not undertake to update any forward-looking information or statements, subject to applicable regulations, in particular Articles 223-1 et seq. of the General Regulation of the French Autorité des Marchés Financiers. Emmanuelle Leygues +33 6 10 93 58 88 [email protected]. media & investors Chris Maggos COHESION BUREAU +41 79 367 6254 [email protected] Ghislaine Gasparetto SEITOSEI ACTIFIN +33 6 21 10 49 24 [email protected] Caroline Carmagnol ALIZE RP +33 6 64 18 99 59 [email protected] KEYWORD: FRANCE EUROPE SOURCE: Median Technologies Copyright Business Wire 2025. PUB: 02/24/2025 11:45 AM/DISC: 02/24/2025 11:45 AM
Associated Press
21-02-2025
- Business
- Associated Press
Bracco and the European Society of Radiology build on long-standing partnership at ECR 2025 through new campaign to advance innovative and sustainable approaches in radiology
Bracco will present an immersive experience at its booth to educate congress attendees on the importance of corporate commitment to sustainability and how its MR imaging portfolio contributes to the progress of sustainable radiology. Bracco will reinforce its commitment to deepening expertise within the radiology community through presentations, a symposium, and open sessions. MILAN, Feb. 21, 2025 /PRNewswire/ -- Bracco, a world leader in diagnostic imaging, announced today that it will showcase an innovative and immersive experience that brings the concept of sustainability to life and expands on 'Planet Radiology' – a campaign launched by the European Society of Radiology (ESR), a nonprofit professional organization dedicated to strengthening and unifying European radiology, at the European Congress of Radiology, taking place in Vienna from February 26 to March 2. In response to the ECR's campaign, Bracco has curated an experience for all congress attendees (Foyer E, Level 0, ACV) titled 'Our Journey to the Future Continues Today, Together, for a Sustainable Tomorrow.' The experience will provide a roadmap to sustainability in medical imaging and highlight technological advances that are transforming medical outcomes and improving patient lives. Specifically, attendees will encounter: 3D-digital pillars featuring statistics for how Bracco's efforts have helped reduce the environmental impact in radiology. Product spotlights demonstrating how Bracco products have specifically been designed to contribute to greater sustainability. An immersive Bracco Dome in which attendees can discover more about Bracco's end-of-life management projects, which are focused on ensuring the proper recycling and disposal of materials used in imaging procedures and are part of Bracco's comprehensive strategy to reduce the environmental footprint of radiology, from production to post-use. Click here for more information about specific presentations within the Dome. 'At Bracco, sustainability is integral to our everyday lifework because we believe that a healthy planet and society create the foundation for healthy people,' said Fulvio Renoldi Bracco, CEO of Bracco Imaging. 'Our vision extends to every part of what we do – from developing an innovative gadolinium-based contrast agent (GBCA) that uses less gadolinium compared to other currently approved macrocyclic GBCAs in their standard recommended doses, to recovering iodinated contrast media, to creating sustainable packaging initiatives that eliminate tertiary cardboard.' 'At ECR 2025, we wish to inspire a more sustainable approach to medical imaging,' said Andrea Rockall, ECR 2025 President. 'It is amazing to see other companies, like Bracco, championing and amplifying this message through a variety of initiatives, many of which we look forward to hearing more about at the congress.' Bracco will also host a series of educational sessions in collaboration with the ESR to advance the field of radiology, including a symposium, open-forum sessions, and an educational event. These sessions will further underline Bracco's commitment to sustainability, with expert-led discussions on the role of artificial intelligence in sustainability, optimizing dosing protocols and contrast management, integrating sustainable practices into daily radiology workflows, and the importance of empowering the next generation of radiologists. Highlights include: AI & Sustainability in radiology: an industry partner perspective on contrast optimization; Moderator: Amy King; Wednesday, February 26, 11.30 – 12.15, Open Forum Area, Foyer E, ACV Level 0. Redefining excellence in contrast-enhanced MRI: the benefits of gadopiclenol, moderated by Francesco Sardanelli. As part of this discussion, don't miss Safety and sustainability: evaluating the impact of reduced dose gadopiclenol, presented by Alberto Spinazzi, which will delve into how gadopiclenol enables dose reduction while enhancing both patient safety and environmental sustainability. Thursday, February 27, 12.30 – 13.00, Room N – ACV Level 1. Bracco and ESR: Young Clubs Take the Lead; Moderator: Federica Vernuccio; Thursday, February 27, 17.30 – 19.30, Room N – AVC Level 1. Photon counting CT and high iodine concentration: a clinical case review; Moderator: Pietro Spagnolo; Friday, February 28, 10.15 – 11.00, Open Forum Area, Foyer E, ACV Level 0. Click here for additional information on the Bracco program at ECR 2025. MEDIA CONTACTS Bracco media contact Carolina Bargoni Bracco Imaging, Communications Director [email protected] D: +39 347 5397738 European Society of Radiology contact David Zizka ESR, Director of Communications About Bracco Imaging Bracco Imaging S.p.A. ('Bracco Imaging'), part of the Bracco Group, is an innovative world leader delivering end-to-end products and solutions through its comprehensive portfolio across diagnostic imaging modalities. Headquartered in Milan, Italy, Bracco Imaging's purpose is to improve people's lives by shaping the future of prevention and precision diagnostic imaging. The Bracco Imaging portfolio includes products and solutions for all key diagnostic imaging modalities: X-ray imaging, magnetic resonance imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents. Bracco Imaging has approximately 3,800 employees and operates in more than 100 markets globally. Bracco Imaging has a well-skilled and innovative Research and Development (R&D) organization with an efficient process-oriented approach and track record in the diagnostic imaging industry. R&D activities are in four centers based in Italy, Switzerland, the United Kingdom and the United States. To learn more about Bracco Imaging, visit About the European Congress of Radiology The ECR is the annual meeting of the European Society of Radiology (ESR), which represents more than 130,000 members from 186 countries worldwide. The ECR is one of the largest medical congresses in the world, attracting thousands of congress participants each year. With hundreds of companies showcasing their products at its technical exhibition, it is also one of the largest medical exhibitions in Europe.
